Tyra Biosciences (NASDAQ:TYRA) Trading Down 4.5% – What’s Next?

Tyra Biosciences, Inc. (NASDAQ:TYRA) shares traded down 4.5% during mid-day trading on Monday . The stock traded as low as $36.66 and last traded at $35.46. 152,089 shares changed hands during trading, a decline of 84% from the average session volume of 948,026 shares. The stock had previously closed at $37.15.

Analysts Set New Price Targets

Several equities analysts have weighed in on TYRA shares. Cantor Fitzgerald assumed coverage on Tyra Biosciences in a research report on Tuesday, February 24th. They issued an “overweight” rating for the company. HC Wainwright raised their price objective on shares of Tyra Biosciences from $30.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Wedbush lifted their price objective on shares of Tyra Biosciences from $37.00 to $53.00 and gave the company an “outperform” rating in a report on Friday, February 13th. Jefferies Financial Group upped their price objective on Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, February 3rd. Finally, Barclays started coverage on shares of Tyra Biosciences in a report on Tuesday, January 27th. They issued an “overweight” rating on the stock. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.67.

Tyra Biosciences Stock Down 1.6%

The company has a 50 day simple moving average of $32.11 and a 200 day simple moving average of $22.98. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of -18.19 and a beta of 1.06.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.03). On average, research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Commodore Capital LP grew its holdings in Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after buying an additional 2,150,000 shares in the last quarter. Farallon Capital Management LLC grew its position in Tyra Biosciences by 80.7% in the 4th quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after buying an additional 923,000 shares in the last quarter. Caligan Partners LP increased its stake in Tyra Biosciences by 266.8% during the 3rd quarter. Caligan Partners LP now owns 696,825 shares of the company’s stock valued at $9,749,000 after buying an additional 506,875 shares during the period. Boone Capital Management LLC acquired a new position in Tyra Biosciences during the 4th quarter valued at about $10,476,000. Finally, Sio Capital Management LLC raised its position in shares of Tyra Biosciences by 94.5% during the 2nd quarter. Sio Capital Management LLC now owns 810,274 shares of the company’s stock worth $7,754,000 after buying an additional 393,657 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.